• Explore /
  • Poster
  • / A multicenter, open‑label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.

A multicenter, open‑label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.

Abstract Poster

Authors

null

Antoni Ribas

David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA

Antoni Ribas , Igor Puzanov , Thomas Gajewski , Georgina V. Long , Reinhard Dummer , John M. Kirkwood , Ari VanderWalde , Jonathan S. Cebon , Grant A. McArthur , Christine K. Gause , Lisa Chen , David Ross Kaufman , Jeffrey Chou , Robert Hans Ingemar Andtbacka , F. Stephen Hodi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Melanoma/Skin Cancers

Clinical Trial Registration Number

NCT02263508

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS9081)

DOI

10.1200/jco.2015.33.15_suppl.tps9081

Abstract #

TPS9081

Poster Bd #

323a

Abstract Disclosures

Similar Posters

First Author: Georgina V. Long

First Author: Paolo Antonio Ascierto

First Author: Deborah J.L. Wong

First Author: Asim Amin